Fang Yuan

Fang Yuan

Auto-generated profile, based on publicly available information

Fang Yuan

Urology Institute of People’s Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, 400038, P.R. China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2012 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MYMingzhen Yang
Mingzhen Yang
FYFang Yuan
Fang Yuan
PLPeng Li
Peng Li
ZCZhongjiao Chen
Zhongjiao Chen
ACAn Chen
An Chen
CHChuanmin Hu
Chuanmin Hu
Background: Our previous work demonstrated that ectopic expression of interferon regulatory factor 4 binding protein (IBP) was correlated with the malignant behaviour of human breast cancer cells. The mechanisms controlling differential expression of IBP in breast cancer still remain unknown. Results: To investigate the mechanism of IBP dysregulation in breast cancer, we identified IBP was a novel p53 target gene. IBP expression was negatively regulated by wild-type p53 and was p53 dependently suppressed by DNA damage agent cisplatin. Furthermore, high levels of IBP were found to decrease cisplatin-induced growth suppression and apoptotic cell death, which was associated with decreased p53 activity and imbalanced Bcl-2 family member expression. Conclusions: IBP is a novel p53 target gene which suppresses cisplatin-mediated apoptosis of breast cancer cells via negative feedback regulation of the p53 signalling pathway, suggesting IBP may serve as a target for pharmacologic intervention of breast cancer resistant to cisplatin therapy.

Verified
Journal Article
Open access
PDF file
YZYi Zhi
Yi Zhi
JYJin Yang
Jin Yang
STShengchao Tian
Shengchao Tian
FYFang Yuan
Fang Yuan
YLYang Liu
Yang Liu
ZCZhiwen Chen
Zhiwen Chen
Topoisomerase I is important for DNA replication and cell division, making it an attractive drug target for anticancer therapy. A series of indenoisoquinolines displaying potent Top1 inhibitory activity in human renal cell carcinoma cell line SN12C were selected to establish 3D-QSAR models using CoMFA and CoMSIA methods. Internal and external cross-validation techniques were investigated, as well as some measures taken, including region focusing, bootstrapping and the “leave-group-out” cross-validation method. The satisfactory CoMFA model predicted a q2 value of 0.659 and an r2 value of 0.949, indicating that electrostatic and steric properties play a significant role in potency. The best CoMSIA model, based on a combination of steric, electrostatic and H-bond acceptor descriptors, predicted a q2 value of 0.523 and an r2 value of 0.902. The models were graphically interpreted by contour plots which provided insight into the structural requirements for increasing the activity of a compound, providing a solid basis for future rational design of more active anticancer agents.